Recipharm Pharmaservices Private Limited

Recipharm Pharmaservices Private Limited is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on December 30, 2015, the company is registered under the Corporate Identification Number (CIN) U24230KA2015PTC084997. Its registered office is located at Flat No. 502, B Wing, Building No. 48, Tilak Indrayani Housing Society, Tilak Nagar (W), Chembur, Mumbai, Maharashtra, 400089.

The company operates with an authorized capital of ₹6,581,000,000 (approximately $88 million USD) and a paid-up capital of ₹183,156,330 (approximately $2.5 million USD). As of the latest available data, Recipharm Pharmaservices employs approximately 1,077 professionals. The company's website is www.recipharm.com.

Recipharm Pharmaservices Private Limited operates manufacturing facilities in India, with a registered office located in Mumbai, Maharashtra. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the capacities and specializations of these facilities are not publicly disclosed.

The leadership team of Recipharm Pharmaservices Private Limited includes:

• Srinivas Rao Davuluri: Appointed as Managing Director on December 8, 2023.

• Ina Quinn: Appointed as Director on January 5, 2023.

• Suresh Nagappa Ganachari: Appointed as Whole-Time Director on November 28, 2022.

Recipharm Pharmaservices Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's total export value is $2.5 million USD, with 64 shipments across four therapeutic categories. The top five exported products are Nitrofurantoin ($1.2 million USD), Isoniazid ($847,000 USD), Theophylline ($317,000 USD), and Torsemide ($138,000 USD). These products are distributed across various markets, including the United States, European Union, United Kingdom, Australia, and Japan. Specific regulatory filings, approvals, and market access statuses in these regions are not publicly disclosed.

Recipharm Pharmaservices Private Limited's export activities also extend to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, such as WHO prequalification, facilitates access to these markets. Specific details regarding market penetration and regulatory approvals in these regions are not publicly disclosed.

Recipharm Pharmaservices Private Limited's export portfolio is concentrated in four therapeutic categories, with the top five products accounting for 100% of the export value. This indicates a high level of portfolio concentration. The company's strategic direction appears to focus on these specific therapeutic areas, leveraging its expertise and manufacturing capabilities to serve both regulated and emerging markets.

Specific details regarding Recipharm Pharmaservices Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's export activities include finished pharmaceutical formulations, which may require FDA approvals for the U.S. market.

Recipharm Pharmaservices Private Limited's adherence to international quality standards, such as WHO Good Manufacturing Practices (GMP) and EU GMP, is essential for accessing global markets. Specific certifications and statuses related to WHO prequalification and EU GMP are not publicly disclosed.

Recipharm Pharmaservices Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are essential for its operations. Specific details regarding these regulatory approvals are not publicly disclosed.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Recipharm Pharmaservices Private Limited. The company's compliance with regulatory standards is crucial for maintaining its export activities.

Recipharm Pharmaservices Private Limited operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific market share comparisons and head-to-head analyses are not publicly available, the company's focus on finished pharmaceutical formulations positions it among competitors in both regulated and emerging markets.

Recipharm Pharmaservices Private Limited's key differentiators include its specialization in finished pharmaceutical formulations, adherence to international quality standards, and a concentrated portfolio in specific therapeutic areas. These factors contribute to the company's competitive advantage in serving diverse markets.

Recipharm Pharmaservices Private Limited's current strategic direction focuses on the production and export of finished pharmaceutical formulations in specific therapeutic categories. The company's future outlook may involve expanding its product portfolio, enhancing manufacturing capabilities, and exploring new market opportunities to strengthen its position in the global pharmaceutical industry.

Recipharm Pharmaservices Private Limited has demonstrated a consistent track record in exporting finished pharmaceutical formulations, with a total export value of $2.5 million USD and 64 shipments across four therapeutic categories. The company's reliability is indicated by its adherence to international quality standards and regulatory compliance, ensuring the consistency and quality of its products.

Importers should verify the following certifications when considering Recipharm Pharmaservices Private Limited as a supplier:

• FDA Approvals: Confirm the company's FDA facility registrations and approved ANDAs for the U.S. market.

• WHO GMP Certification: Ensure the company holds WHO Good Manufacturing Practices certification for compliance with international quality standards.

• EU GMP Certification: Verify the company's EU Good Manufacturing Practices certification for access to European markets.

• ISO Certifications: Check for relevant ISO certifications that demonstrate the company's commitment to quality management systems.

When conducting due diligence on Recipharm Pharmaservices Private Limited, consider the following steps:

• Regulatory Compliance: Verify the company's compliance with relevant regulatory bodies, including the FDA, WHO, EU, and CDSCO.

• Quality Certifications: Confirm the validity of quality certifications such as WHO GMP, EU GMP, and ISO standards.

• Financial Stability: Review the company's financial statements to assess its financial health and stability.

• Supply Chain Reliability: Evaluate the company's supply chain processes to ensure timely and consistent product delivery.

• References and Reviews: Seek references from other clients and review the company's reputation in the industry.

Be vigilant for any discrepancies in regulatory certifications, financial irregularities, or negative feedback from clients, as these may indicate potential risks.